
Private biotech company MacroGenics has licenced its bi-specific antibody platform technology to Gilead Sciences for products aimed at four unnamed …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

